The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study

Intervention(s) in this Clinical Trial

• Drug: Toprol-XL 50 mg
• Drug: Toprol-XL 200 mg
• Drug: Placebo

Inclusion Criteria:

• Diagnosis of stable asymptomatic heart failure.
• Documented ejection fraction less than 0.40.
• Must be able to comply with all study procedures.

Exclusion Criteria:

• Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization.
• Have heart problems that would not allow B-blocker therapy.
• Receiving B-blockers therapy for any medical reason including topical B-blockers that might cause systemic absorption (e.g., glaucoma).
• Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty.
• Have certain heart diseases.
• Pregnant or breast feeding.
• Unlikely to survive.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: AstraZeneca

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00038077

Study ID Number: 276

ClinicalTrials.gov Identifier: NCT00038077

Health Authority: United States: Food and Drug Administration